Amundi Sells 26,895 Shares of Natera, Inc. $NTRA

Key Points

• Amundi reduced its Natera stake by 8.1% in the first quarter, selling 26,895 shares and retaining 306,316 shares valued at approximately $61.3 million. Institutional investors collectively own 99.9% of Natera.
• Other major investors increased their positions, including Maverick Capital, which raised its stake by 24.1%, and OMERS Administration, which increased holdings by 28.2%.
• Analysts remain broadly positive, with Natera holding a “Moderate Buy” consensus rating and an average price target of $267.83. The stock recently opened at $267.76, near its 52-week high of $288.04.

Amundi lessened its stake in Natera, Inc. (NASDAQ:NTRA - Free Report) by 8.1% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 306,316 shares of the medical research company's stock after selling 26,895 shares during the period. Amundi owned 0.21% of Natera worth $61,260,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also added to or reduced their stakes in the company. Royal Bank of Canada boosted its holdings in shares of Natera by 18.1% in the 1st quarter. Royal Bank of Canada now owns 288,069 shares of the medical research company's stock valued at $57,611,000 after buying an additional 44,077 shares in the last quarter. Eversept Partners LP raised its stake in shares of Natera by 15.0% during the 1st quarter. Eversept Partners LP now owns 384,713 shares of the medical research company's stock worth $76,939,000 after acquiring an additional 50,220 shares in the last quarter. Maverick Capital Ltd. lifted its position in Natera by 24.1% during the first quarter. Maverick Capital Ltd. now owns 1,171,633 shares of the medical research company's stock valued at $234,315,000 after acquiring an additional 227,605 shares during the last quarter. Quantinno Capital Management LP boosted its stake in Natera by 8.9% in the first quarter. Quantinno Capital Management LP now owns 61,550 shares of the medical research company's stock valued at $12,310,000 after acquiring an additional 5,007 shares in the last quarter. Finally, OMERS ADMINISTRATION Corp grew its holdings in Natera by 28.2% in the first quarter. OMERS ADMINISTRATION Corp now owns 11,126 shares of the medical research company's stock worth $2,225,000 after purchasing an additional 2,445 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors.

Insider Transactions at Natera

In other Natera news, insider Solomon Moshkevich sold 1,204 shares of the firm's stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $254.07, for a total transaction of $305,900.28. Following the completion of the transaction, the insider directly owned 132,429 shares of the company's stock, valued at approximately $33,646,236.03. This trade represents a 0.90% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Steven Leonard Chapman sold 3,580 shares of the firm's stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $254.07, for a total transaction of $909,570.60. Following the transaction, the chief executive officer directly owned 102,973 shares of the company's stock, valued at $26,162,350.11. This represents a 3.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 173,469 shares of company stock worth $39,310,838. 5.05% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several analysts have recently commented on NTRA shares. UBS Group set a $260.00 price objective on Natera in a report on Wednesday, June 24th. BTIG Research set a $275.00 target price on Natera and gave the stock a "buy" rating in a research note on Wednesday, June 24th. TD Cowen reaffirmed a "buy" rating on shares of Natera in a research report on Wednesday, July 15th. Morgan Stanley raised their price target on Natera from $250.00 to $310.00 and gave the stock an "overweight" rating in a report on Thursday, July 9th. Finally, JPMorgan Chase & Co. boosted their price target on Natera from $260.00 to $265.00 and gave the stock an "overweight" rating in a research note on Friday, May 8th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat, Natera currently has a consensus rating of "Moderate Buy" and an average target price of $267.83.

Natera Stock Performance

Natera stock opened at $267.76 on Monday. The business's 50-day simple moving average is $246.77 and its two-hundred day simple moving average is $222.13. The company has a market cap of $38.35 billion, a PE ratio of -164.27 and a beta of 1.51. Natera, Inc. has a fifty-two week low of $131.81 and a fifty-two week high of $288.04.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.